“We are proud to announce the reinforcement of our Board with Dr Hehenberger, says Erik Nerpin, Chairman of Diamyd Medical. “ Her medical and financial expertise will be of great importance for the further progress of the company” .   

Dr Hehenberger has more than 20 years of experience in the life sciences sector, and is the CEO and founder of a patient empowerment platform, Lyfebulb, headquartered in NYC, USA.  She served as an executive at Eyetech Pharmaceuticals (EYET) and Coronado BioSciences (CNDO) and had strategic management roles at Johnson & Johnson (Vice President Metabolic Strategy), JDRF (Senior Vice President Strategic Alliances), and McKinsey, as well as senior partnership roles at public (Brummer & Partners) and private (Scandinavian Life Science Ventures) multibillion dollar investment funds.  She received her MD and PhD degrees from  Karolinska Institutet, and did her post-doctoral fellowship as a JDRF stipend recipient at the Joslin Diabetes Center, Harvard Medical School. Dr Hehenberger was diagnosed with Type 1 diabetes 31 years ago, and has as her personal mission to improve the outcomes for people living with diabetes.

“It is with great excitement that I join the Board of Diamyd Medical, which is currently at a critical stage of development,” says Karin Hehenberger. “The field of Type 1 diabetes has not seen a major therapeutic or preventative approach since the discovery of insulin 100 years ago, so being part of an effort that could make an impact on a whole population of people living with diabetes, as well as on those not yet diagnosed, was an opportunity that I could not pass on.”

Karin Hehenberger has acquired 10,000 B-shares in Diamyd Medical from its founder and largest shareholder, Anders Essen-Möller.

About Diamyd Medical
Diamyd Medical develops therapies for type 1 diabetes. The diabetes vaccine Diamyd^® is an antigen-specific immunotherapy for the preservation of endogenous insulin production. Significant results have been shown in a genetically predefined patient group in a large-scale meta-analysis as well as in the Company’s European Phase IIb trial DIAGNODE-2, where the diabetes vaccine was administered directly into a lymph node in children and young adults with recently diagnosed type 1 diabetes. A new facility for vaccine manufacturing is being set up in Umeå for the manufacture of recombinant GAD65, the active ingredient in the therapeutic diabetes vaccine Diamyd^®. Diamyd Medical also develops the GABA-based investigational drug Remygen^® as a therapy for regeneration of endogenous insulin production and to improve hormonal response to hypoglycaemia. An investigator-initiated Remygen^® trial in patients living with type 1 diabetes for more than five years is ongoing at Uppsala University Hospital. Diamyd Medical is one of the major shareholders in the stem cell company NextCell Pharma AB.

Diamyd Medical’s B-share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company’s Certified Adviser; phone: +46 8-528 00 399, e-mail: info@fnca.se

For further information, please contact:
Ulf Hannelius, President and CEO
Phone: +46 736 35 42 41
E-mail: ulf.hannelius@diamyd.com

Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
E-mail: info@diamyd.com Reg. no.: 556242-3797 Website: https://www.diamyd.com

The information was provided by the contact person above, for publication on April 20, 2021, 10.25 CET.